Company / SG&A Expense
Aligos Therapeutics, Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$20.7M
FY2025
5-year range
$17.9M / $28.5M
FY2021-FY2025
Trend
-9.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has declined for 3 consecutive years, from $29M in FY2022 to $21M in FY2025.
Based on SEC 10-K filings.
$21M in FY2025 with a 5-year CAGR of +15.7%.
Improved from $26M to $21M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -10.1%
- 5-Year CAGR
- +15.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Aligos Therapeutics, Inc.'s sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of +15.7%, indicating consistent growth.
- In FY2025, sg&a expense decreased 9.3% year-over-year.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $20.7M | -9.3% |
| FY2024 | $22.8M | -13.6% |
| FY2023 | $26.4M | -7.4% |
| FY2022 | $28.5M | +59.0% |
| FY2021 | $17.9M | +79.4% |
| FY2020 | $10.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026